Ono Pharmaceutical Co Ltd 2023 Sustainability Report
The report describes ONO's accelerated environmental program, including carbon neutrality for Scope 1+2 by 2025 and zero emissions by 2035. It reports FY2022 reductions of 38.2% in Scope 1+2 and 30.3% in Scope 3, alongside 21.5% renewable energy use. It also highlights human-rights risk assessment across the Group and supply chain and independent assurance of selected sustainability data.
Company: Ono Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2023
Type: Sustainability Report
Pages: 194
Back to company
Ono Pharmaceutical Co Ltd
Sustainability Report
The report describes ONO's accelerated environmental program, including carbon neutrality for Scope 1+2 by 2025 and zero emissions by 2035. It reports FY2022 reductions of 38.2% in Scope 1+2 and 30.3% in Scope 3, alongside 21.5% renewable energy use. It also highlights human-rights risk assessment across the Group and supply chain and independent assurance of selected sustainability data.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Published
Nov 1, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees